BRAF mutation

Quiénes somos

• enero 17, 2024

  Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC

• 5 de abril de 2022

  Dabrafenib + Trametinib + PDR001 en cáncer colorrectal